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Background
HIV-1 seronegative individuals exist who, despite
repeated high-level exposure to HIV-1, fail to seroconvert.
One explanation for this phenomenon is the existence of
protective HIV-1 specific T-cell responses. In order to
address this issue, we have established an MSM cohort at
St Mary's STI clinic in London.
Methods
This cohort includes serodiscordant couples, consisting of
one HIV positive and one exposed uninfected (EU) indi-
vidual, and monogamous unexposed, uninfected (UU)
couples. Strict criteria are used to enrol couples into these
groups. The study is blinded and has been designed so
that it has significant statistical power to detect whether
there is a true difference in T cell responses between the
EU and UU groups. Participants donate samples and
answer a detailed sexual behaviour questionnaire (SBQ)
during 4 visits, 3 months apart. PBMCs are isolated and
used for ex vivo and highly-sensitvie cultured IFN-gamma
ELISpot assays. In the cultured assay, antigen-specific T-
cells populations are expanded and positive responses in
EU and UU samples are further characterised to identify
the individual peptide antigen recognised and whether
responses are CD4 or CD8 restricted.
Results
Enrolment for this study ceased in April, 2009, and initial
T cell and SBQ analyses of all visit 1 data will be presented
in this poster. Partial analysis of visit 1 showed T-cell
responses in EU participants in 62% (8/13) cases and in
UU participants in 32% (7/22) cases. Full analyses will
include overall response rates, as well as whether specific
responses are maintained longitudinally. Within the EU
group, T cell responses are also being correlated with the
presence of STIs, partner's viral load, and risk/exposure
index.
Conclusion
Initial analysis suggests a difference in the rate of HIV-1
specific T-cell responses in EU and UU individuals,
although full statistical analysis is on going.
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